Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Thursday. The firm currently has a $15.00 price target on the stock. Zacks Investment Research‘s target price suggests a potential upside of 13.90% from the stock’s previous close.
According to Zacks, “Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company discovers and develops oral drug candidates to treat inflammation and cancer. Aquinox Pharmaceuticals, Inc. is headquartered in Vancouver, Canada. “
A number of other equities analysts also recently commented on AQXP. Cantor Fitzgerald set a $28.00 target price on Aquinox Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, May 9th. ValuEngine upgraded Aquinox Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. BidaskClub downgraded Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, July 28th. Finally, Canaccord Genuity set a $22.00 target price on Aquinox Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $22.25.
Shares of Aquinox Pharmaceuticals (AQXP) opened at 13.17 on Thursday. The stock’s 50 day moving average is $14.49 and its 200 day moving average is $15.46. Aquinox Pharmaceuticals has a 12 month low of $8.76 and a 12 month high of $19.97. The firm’s market cap is $308.48 million.
Aquinox Pharmaceuticals (NASDAQ:AQXP) last announced its earnings results on Tuesday, August 8th. The company reported ($0.59) EPS for the quarter, meeting analysts’ consensus estimates of ($0.59). Equities research analysts expect that Aquinox Pharmaceuticals will post ($2.15) EPS for the current year.
ILLEGAL ACTIVITY WARNING: This piece was posted by Stock Observer and is owned by of Stock Observer. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be read at https://www.thestockobserver.com/2017/08/12/aquinox-pharmaceuticals-inc-nasdaqaqxp-upgraded-at-zacks-investment-research.html.
In other Aquinox Pharmaceuticals news, insider David Main sold 15,625 shares of the stock in a transaction on Monday, June 5th. The stock was sold at an average price of $13.26, for a total value of $207,187.50. Following the completion of the transaction, the insider now owns 77,530 shares in the company, valued at $1,028,047.80. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 2.70% of the stock is currently owned by corporate insiders.
Institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. increased its position in Aquinox Pharmaceuticals by 6.6% in the second quarter. Vanguard Group Inc. now owns 282,483 shares of the company’s stock worth $3,974,000 after buying an additional 17,455 shares during the period. Geode Capital Management LLC increased its position in Aquinox Pharmaceuticals by 10.0% in the first quarter. Geode Capital Management LLC now owns 121,532 shares of the company’s stock worth $2,028,000 after buying an additional 11,035 shares during the period. Northern Trust Corp increased its position in Aquinox Pharmaceuticals by 3.3% in the second quarter. Northern Trust Corp now owns 83,207 shares of the company’s stock worth $1,171,000 after buying an additional 2,691 shares during the period. Sphera Funds Management LTD. purchased a new position in Aquinox Pharmaceuticals during the second quarter worth about $874,000. Finally, Bank of New York Mellon Corp increased its position in Aquinox Pharmaceuticals by 16.5% in the second quarter. Bank of New York Mellon Corp now owns 23,260 shares of the company’s stock worth $327,000 after buying an additional 3,299 shares during the period. Institutional investors and hedge funds own 98.32% of the company’s stock.
About Aquinox Pharmaceuticals
Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aquinox Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.